返回

Halozyme revenue jumps 48% in Q2 2026 on royalty growth

  • Halozyme Therapeutics reported higher revenue in Q2 2026.
  • Revenue increased 48%, while royalty revenue rose 50% year over year.
  • Halozyme is shifting beyond dependence on DARZALEX SC.

Halozyme Therapeutics reported a 48% year-over-year increase in revenue for the second quarter of 2026. Royalty revenue climbed 50%, and EBITDA margins reached 68%. The company is transitioning from reliance on its single product, DARZALEX SC, toward a broader portfolio.

本网站上的信息是使用AI生成的，我们无法保证其准确性。 请仅作为参考信息使用。